New Staphylococcus Findings from First Hospital of Jilin University Described (Laurocapram, a Transdermal Enhancer, Boosts Cephalosporin's ' S Antibacterial Activity Against Methicillin-resistant Staphylococcus Aureus).

A recent study conducted at the First Hospital of Jilin University in Changchun, China, has found that the chemical transdermal enhancer laurocapram can enhance the antibacterial activity of cephalosporins against methicillin-resistant Staphylococcus aureus (MRSA). The researchers conducted in vitro tests and animal models to demonstrate the synergistic effect of laurocapram and cefixime in combating MRSA infections. This discovery suggests that laurocapram could be a promising and cost-effective adjuvant for lower doses of cephalosporins in the treatment of MRSA infections. The study was supported by the National Natural Science Foundation of China and other funding sources. [Extracted from the article]